{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:34:46Z","timestamp":1777055686633,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Therapeutic drug monitoring (TDM) of anti-TNF biologics may help optimise treatment in rheumatoid arthritis (RA), but current therapeutic ranges do not always reflect clinical response in routine practice. Methods: We conducted a retrospective observational study including 224 adults with RA treated with infliximab (IFX), adalimumab (ADL), or etanercept (ETN) during the maintenance phase at Hospital Universitario Puerto Real between May 2016 and May 2023. Drug and anti-drug antibody levels were measured by sandwich ELISA and analysed against clinical response using DAS28. Demographic and clinical variables, associations between drug levels and response, the effect of antibodies, correlations between serum concentrations and DAS28, and the performance of current and proposed therapeutic ranges were evaluated. Results: The cohort was mainly female (62.1%), with a mean age of 57.7 years, BMI of 28.5 kg\/m2, and mean DAS28 of 3.33. ETN was most frequently used (62.5%), followed by ADL (21.9%) and IFX (15.6%). Drug levels were significantly associated with response (p &lt; 0.001). Anti-drug antibodies were strongly linked to non-response, especially with IFX and ADL. Serum drug levels correlated inversely with disease activity for IFX and ADL, but not for ETN. Current therapeutic ranges showed low sensitivity, while lower proposed ranges improved sensitivity considerably. Conclusions: Current anti-TNF therapeutic ranges have limited ability to identify responders in real-world RA. Lowering the lower bound improves sensitivity and supports more individualised TDM, particularly for IFX and ADL, pending prospective validation.<\/jats:p>","DOI":"10.3390\/life16050723","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:26:18Z","timestamp":1777051578000},"page":"723","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising Therapeutic Intervals for Anti-TNF Biologics in Rheumatoid Arthritis: A Retrospective Real-World Study"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9731-6105","authenticated-orcid":false,"given":"Jose Manuel","family":"Dodero-Anillo","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Hospital Universitario Puerto Real, 11510 Cadiz, Spain"},{"name":"Faculty of Medicine, University of Cadiz, 11009 Cadiz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-2495","authenticated-orcid":false,"given":"Manuel","family":"Rosety-Rodriguez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Cadiz, 11009 Cadiz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jose","family":"Pedrosa-Martinez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Hospital Universitario Puerto Real, 11510 Cadiz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid arthritis pathogenesis, prediction, and prevention: An emerging paradigm shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"21551","DOI":"10.1038\/s41598-020-76511-6","article-title":"The prevalence of rheumatoid arthritis in Spain","volume":"10","author":"Brandy","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_3","unstructured":"Sociedad Espanola de Reumatologia (SER) (2019). GUIPAR\u201919. Clinical Practice Guidelines for the Management of Patients with Rheumatoid Arthritis, SER."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102400","DOI":"10.1016\/j.jaut.2019.102400","article-title":"The etiology of rheumatoid arthritis","volume":"110","author":"Scherer","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00281-022-00912-0","article-title":"Genetics of rheumatoid arthritis","volume":"44","author":"Padyukov","year":"2022","journal-title":"Semin Immunopathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-021-00993-0","article-title":"Etiologies of rheumatoid arthritis: Update on mucosal, genetic, and cellular pathogenesis","volume":"23","author":"Kronzer","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., and Yang, S.-H. (2021). The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lin, Y.J., Anzaghe, M., and Schulke, S. (2020). Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells, 9.","DOI":"10.3390\/cells9040880"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatology"},{"key":"ref_12","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"Renskers","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/1744666X.2019.1630273","article-title":"Therapeutic drug monitoring with biologic agents in immune-mediated inflammatory diseases","volume":"15","author":"Papamichael","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","first-page":"394","article-title":"Anti-tumor necrosis factor drug therapy: The usefulness of monitoring drug levels and anti-drug antibodies in clinical practice","volume":"147","year":"2016","journal-title":"Med. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13862","article-title":"Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","first-page":"462","article-title":"Association between overweight\/obesity and clinical activity in rheumatoid arthritis","volume":"16","year":"2020","journal-title":"Reumatol. Clin."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.reuma.2020.08.006","article-title":"The association between smoking and the development of rheumatoid arthritis: A population-based case-control study","volume":"17","author":"Nagra","year":"2021","journal-title":"Reumatol. Clin."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/rheumatology\/ken057","article-title":"Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than non-smokers of the same serological group","volume":"47","author":"Westhoff","year":"2008","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/03009742.2010.541495","article-title":"Smoking at onset of rheumatoid arthritis and its effect on disease activity and functional status: Experiences from BARFOT, a long-term observational study on early RA","volume":"40","author":"Petersson","year":"2011","journal-title":"Scand. J. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.27758","article-title":"Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts","volume":"63","author":"Saevarsdottir","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/RHU.0b013e3181ca4a2a","article-title":"Anti-TNF-\u03b1 agents are less effective for the treatment of rheumatoid arthritis in current smokers","volume":"16","author":"Abhishek","year":"2010","journal-title":"J. Clin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/rheumatology\/kel149","article-title":"Predictors of response to anti-TNF-\u03b1 therapy among patients with rheumatoid arthritis","volume":"45","author":"Hyrich","year":"2006","journal-title":"Rheumatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: A randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Plasencia","year":"2011","journal-title":"Rheumatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of anti-drug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","article-title":"Key findings towards optimising adalimumab treatment: The concentration\u2013effect curve","volume":"74","author":"Pouw","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","unstructured":"Puerto Real University Hospital (2021, September 15). Reference Population 2021. [Hospital\u2019s Internal Public Records]. Available online: https:\/\/www.juntadeandalucia.es\/institutodeestadisticaycartografia\/sima\/nucleos.htm?CodMuni=11028."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/jnc.13108","article-title":"Development of mature BDNF-specific sandwich ELISA","volume":"134","author":"Lim","year":"2015","journal-title":"J. Neurochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.reuma.2020.10.006","article-title":"Status, control, impact, and current management of rheumatoid arthritis according to patients: National survey AR 2020","volume":"18","author":"Alcaide","year":"2022","journal-title":"Reumatol. Clin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3899\/jrheum.081096","article-title":"Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis","volume":"36","author":"Mattey","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_33","first-page":"475","article-title":"Anti-TNF\u03b1 drug levels in patients with rheumatoid arthritis and spondyloarthritis","volume":"18","year":"2022","journal-title":"Reumatol. Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann. Rheum. Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:36:10Z","timestamp":1777052170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/5\/723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["life16050723"],"URL":"https:\/\/doi.org\/10.3390\/life16050723","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}